UY37473A - Pirido[3,4-b]indoles sustituidos y su uso como productos farmacéuticos - Google Patents

Pirido[3,4-b]indoles sustituidos y su uso como productos farmacéuticos

Info

Publication number
UY37473A
UY37473A UY0001037473A UY37473A UY37473A UY 37473 A UY37473 A UY 37473A UY 0001037473 A UY0001037473 A UY 0001037473A UY 37473 A UY37473 A UY 37473A UY 37473 A UY37473 A UY 37473A
Authority
UY
Uruguay
Prior art keywords
pirido
pharmaceutical products
substituted indoles
substituted
cartilage
Prior art date
Application number
UY0001037473A
Other languages
English (en)
Inventor
Dirk Gretzke
Olaf Ritzeler
Uwe Heinelt
Volkmar Wehner
Friedemann Schmidt
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY37473A publication Critical patent/UY37473A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a 9h-pirido[3,4-b]indoles sustituidos con 8-arilo y sustituidos 5 con 8-heteroarilo de fórmula i, en la que a, e, g, R1 a R6 y R10 son como se definen en las reivindicaciones, que estimulan la condrogénesis y la síntesis de la matriz del cartílago y se pueden usar en el tratamiento de trastornos y afecciones del cartílago en los que se desea la regeneración del cartílago dañado, por ejemplo, enfermedades de las articulaciones tales como la osteoartritis. La invención se refiere además a procedimientos para la síntesis de los compuestos de fórmula i.
UY0001037473A 2016-11-07 2017-11-07 Pirido[3,4-b]indoles sustituidos y su uso como productos farmacéuticos UY37473A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306452.0A EP3318563A1 (en) 2016-11-07 2016-11-07 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Publications (1)

Publication Number Publication Date
UY37473A true UY37473A (es) 2018-06-29

Family

ID=57286428

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037473A UY37473A (es) 2016-11-07 2017-11-07 Pirido[3,4-b]indoles sustituidos y su uso como productos farmacéuticos

Country Status (35)

Country Link
US (2) US11130755B2 (es)
EP (3) EP3318563A1 (es)
JP (1) JP7046063B2 (es)
KR (1) KR102490199B1 (es)
CN (1) CN110382496B (es)
AR (1) AR110136A1 (es)
AU (2) AU2017353381B2 (es)
BR (1) BR112019007901A2 (es)
CA (1) CA3042332A1 (es)
CL (1) CL2019001251A1 (es)
CO (1) CO2019005090A2 (es)
CR (1) CR20190217A (es)
DK (1) DK3535263T3 (es)
DO (1) DOP2019000112A (es)
EA (1) EA038365B1 (es)
EC (1) ECSP19031458A (es)
ES (1) ES2837765T3 (es)
HR (1) HRP20201754T1 (es)
HU (1) HUE052187T2 (es)
IL (1) IL265982B (es)
LT (1) LT3535263T (es)
MA (1) MA45803B1 (es)
MX (1) MX2019005308A (es)
MY (1) MY189589A (es)
PE (1) PE20191032A1 (es)
PH (1) PH12019500997A1 (es)
PT (1) PT3535263T (es)
RS (1) RS61172B1 (es)
SG (1) SG11201903195YA (es)
SI (1) SI3535263T1 (es)
TN (1) TN2019000143A1 (es)
TW (1) TWI753966B (es)
UY (1) UY37473A (es)
WO (1) WO2018083157A1 (es)
ZA (1) ZA201902111B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
US11547712B2 (en) 2017-11-20 2023-01-10 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11788064B2 (en) 2018-01-05 2023-10-17 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11485734B2 (en) 2018-10-02 2022-11-01 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)
JP2022543460A (ja) * 2019-08-06 2022-10-12 ドメイン・セラピューティクス 神経ペプチドff受容体アンタゴニストとしての5-ヘテロアリール-ピリジン-2-アミン化合物
CN114763347A (zh) * 2021-01-15 2022-07-19 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
ECSP951529A (es) 1995-09-05 1997-05-16 Compuestos farmaceuticos
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
JP4599501B2 (ja) 2001-11-07 2010-12-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 多発性骨髄腫および他の癌の処置におけるIκBのインヒビターとしてのカルボリン誘導体
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
WO2006013739A1 (ja) * 2004-08-04 2006-02-09 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、照明装置及び表示装置
JP5815206B2 (ja) 2006-08-25 2015-11-17 アレス トレーディング ソシエテ アノニム Fgf−18を用いた軟骨障害の治療
WO2008132454A1 (en) 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
WO2010038153A1 (en) 2008-10-01 2010-04-08 The University Of British Columbia Use of sox transcription factor acti\ators for stimulating chondrogenesis
EP2455378A1 (en) * 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
JP5854492B2 (ja) 2011-02-24 2016-02-09 国立大学法人 岡山大学 軟骨細胞分化誘導促進剤
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Also Published As

Publication number Publication date
CN110382496B (zh) 2022-08-09
AR110136A1 (es) 2019-02-27
EP3792262A1 (en) 2021-03-17
CL2019001251A1 (es) 2019-10-04
AU2017353381A1 (en) 2019-05-30
CA3042332A1 (en) 2018-05-11
JP2019537587A (ja) 2019-12-26
AU2021221468B2 (en) 2023-10-26
KR20190072654A (ko) 2019-06-25
DOP2019000112A (es) 2019-07-31
DK3535263T3 (da) 2020-12-21
US11130755B2 (en) 2021-09-28
TN2019000143A1 (en) 2020-10-05
TWI753966B (zh) 2022-02-01
EA038365B1 (ru) 2021-08-16
MA45803A1 (fr) 2020-05-29
AU2021221468A1 (en) 2021-09-16
BR112019007901A2 (pt) 2019-07-02
EA201991144A1 (ru) 2019-10-31
HRP20201754T1 (hr) 2020-12-25
KR102490199B1 (ko) 2023-01-20
HUE052187T2 (hu) 2021-04-28
TW201831475A (zh) 2018-09-01
CN110382496A (zh) 2019-10-25
ECSP19031458A (es) 2019-05-31
SG11201903195YA (en) 2019-05-30
PH12019500997A1 (en) 2019-08-05
MY189589A (en) 2022-02-18
RS61172B1 (sr) 2021-01-29
MA45803B1 (fr) 2020-10-28
IL265982A (en) 2019-06-30
LT3535263T (lt) 2020-12-28
PT3535263T (pt) 2020-12-18
WO2018083157A1 (en) 2018-05-11
ZA201902111B (en) 2020-10-28
ES2837765T3 (es) 2021-07-01
IL265982B (en) 2021-05-31
PE20191032A1 (es) 2019-08-05
US20200095242A1 (en) 2020-03-26
EP3318563A1 (en) 2018-05-09
EP3535263B1 (en) 2020-09-30
MX2019005308A (es) 2019-08-05
US20220041596A1 (en) 2022-02-10
EP3535263A1 (en) 2019-09-11
CR20190217A (es) 2019-08-06
SI3535263T1 (sl) 2020-11-30
JP7046063B2 (ja) 2022-04-01
US11827633B2 (en) 2023-11-28
AU2017353381B2 (en) 2021-05-27
CO2019005090A2 (es) 2019-07-31

Similar Documents

Publication Publication Date Title
UY37473A (es) Pirido[3,4-b]indoles sustituidos y su uso como productos farmacéuticos
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
UY36226A (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
CR20130339A (es) Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY31623A1 (es) Compuestos y composiciones como inhibidores de cinasa
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20160574A (es) Compuestos de dihidroisoquinolinona sustituida
DOP2014000230A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
DOP2020000072A (es) Amidas de imidazopiridina sustituidas y su uso
CO2017005588A2 (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
AR090241A1 (es) INHIBIDORES DE LA b-SECRETASA
UY35012A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
PE20170088A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
UY32754A (es) NUEVOS DERIVADOS DE 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA
AR092247A1 (es) INHIBIDORES DE LA b-SECRETASA

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230705